Sign up online today & collaborate
or click here to find out more
Oxford, UK – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and
Dr Roblin has had a highly successful career in the life sciences industry, including senior leadership roles at Pfizer and Bayer, which involved overseeing the research, development and commercial launch of drugs across several therapy areas including infectious diseases. Dr Roblin’s most recent role was COO and Director of Scientific Translation at the Francis Crick Institute, a London-based biomedical institute dedicated to understanding the fundamental biology underlying health and disease.
Mr Glyn Edwards, Chief Executive Officer of Summit said:
“Summit has two strong scientific programmes with the potential to significantly advance the current standard of care in their respective disease areas. In CDI, the positive results from Summit’s Phase 2 proof of concept trial highlight ridinilazole’s impressive translational medicine story, and in DMD, we are nearing the first data from our Phase 2 trial of ezutromid evaluating the mechanism for utrophin modulation,”
|Company||Summit Therapeutics plc|